Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20654699 | 0.84 | HSP90AB1 (0.49) | HDAC1HDAC6HDAC5HDAC8HSP90AB1 | |
| SCHEMBL21543796 | 0.82 | HDAC6 (0.73) | HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL20640472 | 0.82 | HDAC4 (0.50) | HDAC1HDAC6HDAC5HDAC8S1PR1 | |
| SCHEMBL21407190 | 0.81 | SPHK2 (0.58) | CYP19A1HDAC1HDAC6HDAC8 | |
| SCHEMBL21407333 | 0.80 | HDAC6 (0.55) | HDAC1HDAC6HDAC5HDAC8S1PR1 | |
| SCHEMBL21407161 | 0.80 | HDAC6 (0.48) | HDAC1HDAC6HDAC8S1PR1 | |
| SCHEMBL22958917 | 0.78 | HDAC6 (0.53) | HDAC1HDAC6HDAC8 | |
| SCHEMBL21407448 | 0.77 | HDAC6 (0.50) | HDAC1HDAC6HDAC8 | |
| SCHEMBL84637 | 0.77 | CYP19A1 (1.00) | CYP19A1HSP90AB1 | |
| SCHEMBL20651113 | 0.76 | HDAC4 (0.53) | HDAC1HDAC6HDAC5HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-03-01 | — | — | US | disclosed |
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210037826-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | CYP19A1 422/4885HDAC1 551/4885HDAC6 610/4885 |
| US-10798941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | CYP19A1 467/4885HDAC1 580/4885HDAC6 592/4885 |
| US-20190297892-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | CYP19A1 467/4885HDAC1 580/4885HDAC6 592/4885 |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | CYP19A1 422/4885HDAC1 551/4885HDAC6 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.